Drug
Lixisenatide clinical trials
Also written Lyxumia.
- studies test it
- 57
- open now
- 3
- in phase 3
- 30
- first study started
- 2006
Keep track of what changes. Save the lixisenatide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Lyxumia
- 11
Combined with it in one product
Studies by the year they started
57 studies that test it; most in 2008 (7)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 7 |
| 2009 | 5 |
| 2010 | 4 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 6
- Phase 3
- 30
- Phase 4
- 14
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 41 · Other 16
Sanofi (40) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · University Hospital, Toulouse (1) · Population Health Research Institute (1) · University of Campania Luigi Vanvitelli (1) · University Hospital, Gentofte, Copenhagen (1) · Seoul National University Hospital (1) · Medical University of Vienna (1)
Often tested with
Tested in the same studies.
Insulin Glargine (20) · Metformin (2) · IDegLira (1) · Liraglutide (1) · Dulaglutide (1)
Studies
Open first, then newest update. How each study uses lixisenatide is read from its arms, and is right about nine times in ten.
Testing it · 57
- iGlarLixi CGM Study in Chinese T2D Individuals After OADsRecruitingPhase 4SanofiNCT06671587Written as iGlarLixi (insulin glargine/lixisenatide)
- Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced DiabetesEnrolling by invitationPhase 4Medical University of WarsawNCT07117240Written as lixisenatide + glargine
- The Effect of Lixisenatide on the Effect of Pituitary HormonesRecruitingPhase 4University of TartuNCT05804513Written as Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector
- Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver DiseaseActive, not recruitingPhase 4The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07274644Written as iGlarLixi
- Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseCompletedPhase 2University Hospital, ToulouseNCT03439943Written as Lixisenatide
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)CompletedPhase 3SanofiNCT05413369Written as Insulin glargine/Lixisenatide
- Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusCompletedPhase 4SanofiNCT05114590Written as Insulin glargine/Lixisenatide
- Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 DiabetesStatus unknownPhase 4Chungbuk National University HospitalNCT04893148Written as IGlarLixi
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinCompletedPhase 3SanofiNCT03798080Written as Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)CompletedPhase 3SanofiNCT03798054Written as Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanCompletedPhase 4SanofiNCT02941367Written as Lixisenatide (AVE0010)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)CompletedPhase 3SanofiNCT03529123Written as INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)
- A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1SanofiNCT02803918Written as Lixisenatide (AVE0010)
- Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsTerminatedPhase 3SanofiNCT03434119Written as Insulin glargine/Lixisenatide
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompletedPhase 3SanofiNCT02787551Written as Insulin glargine/lixisenatide fixed ratio combination
- INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixiStatus unknownPhase 4Institute for Clinical and Experimental MedicineNCT04945070Written as IGlarLixi
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixiCompletedPhase 3Population Health Research InstituteNCT03130426Written as iGlarLixi
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)CompletedPhase 4University of Campania Luigi VanvitelliNCT04196231Written as IGlarLixi
- Effects of Insulin Glargine and Lixisenatide on the BrainTerminatedPhase 4University Hospital TuebingenNCT03881995Written as IGlarLixi
- Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsCompletedPhase 3SanofiNCT02752412Written as Insulin glargine/Lixisenatide (HOE901/AVE0010)
See all 57 studies that test lixisenatide →
Given in every arm · 1 — lixisenatide is usual care beside what is tested
As the comparator · 2 — what is tested is compared with lixisenatide
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DMCompletedPhase 3SanofiNCT02058147Written as Lixisenatide (AVE0010)
- Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 DiabetesCompletedPhase 4Novo Nordisk A/SNCT01973231Written as lixisenatide
Codes
What other systems call lixisenatide · ClinicalTrials.gg INT004587
- MeSH (NLM) C479460lixisenatideOne source NLM
- UNII (FDA) 74O62BB01ULIXISENATIDEConfirmed FDA, NLM
- RxNorm 1440051One source FDA
- NCI Thesaurus C166988LixisenatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C479460 | lixisenatide | One source NLM |
| UNII (FDA) | 74O62BB01U | LIXISENATIDE | Confirmed FDA, NLM |
| RxNorm | 1440051 | — | One source FDA |
| NCI Thesaurus | C166988 | Lixisenatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.